Source-grounded facts extracted from DYADIC INTERNATIONAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DYADIC INTERNATIONAL INC shareholders approved Advisory vote on compensation of the Company’s named executive officers as described in the Proxy Statement. at the 2026-06-18 meeting.
“Proposal 4: Advisory vote on compensation of the Company’s named executive officers as described in the Proxy Statement. For Against Abstained Broker Non-Votes 18,213,001 343,799 739,157 10,313,240”
DYADIC INTERNATIONAL INC shareholders approved Ratification of appointment of Crowe LLP as the Company’s independent registered public accounting firm for the current fiscal year ending December 31, 2026. at the 2026-06-18 meeting.
“Proposal 3: Ratification of appointment of Crowe LLP as the Company’s independent registered public accounting firm for the current fiscal year ending December 31, 2026. For Against Abstained 28,623,686 517,907 467,604”
DYADIC INTERNATIONAL INC shareholders approved To approve the board of directors’ authorization to effect, at its discretion, a reverse stock split of the Company’s common stock, by a ratio in the range set forth in the Company’s Definitive Proxy Statement on Schedule 14A relating to the 2026 Annual Meeting (the “Proxy Statement”). at the 2026-06-18 meeting.
“Proposal 2: To approve the board of directors’ authorization to effect, at its discretion, a reverse stock split of the Company’s common stock, by a ratio in the range set forth in the Company’s Definitive Proxy Statement on Schedule 14A relating to the 2026 Annual Meeting (the “Proxy Statement”). For Against Abstained 25,419,068 3,725,962 464,167”
DYADIC INTERNATIONAL INC shareholders approved Election of Class I director to serve until the Company’s 2029 Annual Meeting of Shareholders. at the 2026-06-18 meeting.
“Proposal 1: Election of Class I director to serve until the Company’s 2029 Annual Meeting of Shareholders. Nominee For Withheld Broker Non-Votes Seth J. Herbst, M.D 18,121,850 1,174,107 10,313,240”
DYADIC INTERNATIONAL INC received a nasdaq delisting notice notice regarding other (rules 5550(b)).
“June 18, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has initiated a process that could result in the delisting of the Company’s securities from Nasdaq due to the Company’s failure to comply with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), which requires listed companies to maintain a minimum bid price of $1.00 per share. As previously disclosed, in accordance with the Bid Price Rule, the Company was provided 180 calendar days, or until June 17”
DYADIC INTERNATIONAL INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).
“June 18, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has initiated a process that could result in the delisting of the Company’s securities from Nasdaq due to the Company’s failure to comply with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), which requires listed companies to maintain a minimum bid price of $1.00 per share. As previously disclosed, in accordance with the Bid Price Rule, the Company was provided 180 calendar days, or until June 17”
DYADIC INTERNATIONAL INC reported financial results for Q1 2026.
“Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2026.”
DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).
“March 27, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is out of compliance with the technical minimum requirements for continued listing under Nasdaq Listing Rule 5550(b) (the “Continued Listing Requirement”). The Continued Listing Requirement requires the Company to maintain at least one of the following: $2.5 million in stockholders’ equity; $35 million in market value of listed securities; or $500,000”
DYADIC INTERNATIONAL INC reported financial results for the year ended December 31, 2025.
“On March 25, 2026, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the year ended December 31, 2025.”
DYADIC INTERNATIONAL INC entered into At-The-Market Issuance Sales Agreement with Craig-Hallum Capital Group LLC valued at up to $4,237,818 (effective 2026-03-06).
“On March 6, 2026, Dyadic International, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC, as sales agent (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time, at its option, shares of the Company’s common stock having an aggregate offering price of up to $4,237,818”
DYADIC INTERNATIONAL INC amended Amendment (effective 2025-12-23).
“On December 23, 2025, Dyadic International, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Form of Senior Secured Convertible Promissory Note due March 8, 2027 (the “Convertible Notes”).”
DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 19, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5”
DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).
“July 17, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(”
DYADIC INTERNATIONAL INC received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
“June 23, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum Market Value of Listed Securities (“MVLS”) of $35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Na”
DYADIC INTERNATIONAL INC: Amended and restated the Third Amended and Restated Bylaws to clarify election inspector roles, virtual meeting procedures, stockholder list provisions, and update officer and board committee meeting provisions (effective 2025-05-29).
“On May 29, 2025, the Board amended and restated the Company’s Third Amended and Restated Bylaws (as amended and restated, the “Bylaws”), effective immediately.”
Joseph Hazelton was appointed as President at DYADIC INTERNATIONAL INC.
“On May 29, 2025, the board of directors (the "Board") of Dyadic International, Inc. (the "Company") appointed Joseph Hazelton as President of the Company.”
Arindam Bose retired as Director at DYADIC INTERNATIONAL INC.
“On April 28, 2025, Arindam Bose notified the board of directors (the “Board”) of Dyadic International, Inc. (the “Company”) of his decision to retire as a director of the Board, effective at the Company’s annual meeting to be held on June 20, 2025.”
DYADIC INTERNATIONAL INC reported financial results for first quarter of 2024.
“On May 14, 2024, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2024.”
Joseph Hazelton was appointed as Chief Operating Officer at DYADIC INTERNATIONAL INC.
“the Board appointed Joseph Hazelton, its current Chief Business Officer, to the position of Chief Operating Officer, effective immediately.”
Barry C. Buckland retired as Director at DYADIC INTERNATIONAL INC.
“Dr. Barry C. Buckland notified the Board of his decision to retire as a director of the Board, effective at the Company’s annual meeting to be held in June 2024.”
Michael Tarnok retired as Director at DYADIC INTERNATIONAL INC.
“Mr. Tarnok notified the Board of his decision to retire as a director of the Board, effective at the Company’s annual meeting to be held in June 2025.”
Patrick Lucy was appointed as Chairman of the Board at DYADIC INTERNATIONAL INC.
“appointed current member of the Board Patrick Lucy as its Chairman”
DYADIC INTERNATIONAL INC incurred convertible notes of $6,000,000 with immediate family members and family trusts related to Mark Emalfarb, including The Francisco Trust U/A/D February 28, 1996 at 8% per annum maturing March 8, 2027.
“On March 8, 2024, Dyadic International, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 in an aggregate principal amount of $6.0 million (the “Convertible Notes”).”
DYADIC INTERNATIONAL INC entered into Securities Purchase Agreement with The Francisco Trust U/A/D February 28, 1996 and immediate family members and family trusts related to Mark Emalfarb valued at $6.0 million (effective 2024-03-08).
“On March 8, 2024, Dyadic International, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued 8.0% Senior Secured Convertible Promissory Notes due March 8, 2027 in an aggregate principal amount of $6.0 million (the “Convertible Notes”).”
DYADIC INTERNATIONAL INC terminated Research, License, and Collaboration Agreement with Janssen Biotech, Inc. (effective 2023-12-31).
“Pursuant to Section 12.3 of the Agreement, on October 2, 2023, Janssen provided written notice to Dyadic that it has decided to wind down the collaboration with an effective end date of December 31, 2023.”
DYADIC INTERNATIONAL INC entered into Development and Exclusive License Agreement with INZYMES ApS valued at upfront payment of $0.6 million (effective 2023-09-18).
“On September 18, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc. (“Dyadic” or the “Company”) signed a Development and Exclusive License Agreement (the “Agreement”) with INZYMES ApS (“INZYMES”), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic’s proprietary DapibusTM platform.”
DYADIC INTERNATIONAL INC reported financial results for the second quarter of 2023.
“On August 9, 2023, Dyadic International, Inc. ("Dyadic") issued a press release announcing its results for the quarter ended June 30, 2023.”
DYADIC INTERNATIONAL INC shareholders approved Advisory Vote on compensation of the Company's Named Executive Officers.
“Proposal 3: Advisory Vote on compensation of the Company's Named Executive Officers. For % Votes Cast For Against Abstained Broker Non-Votes 15,549,508 97.61 % 380,176 58,494 7,403,482”
DYADIC INTERNATIONAL INC shareholders approved Ratification of Appointment of Crowe LLP as the Company's Independent Registered Public Accounting Firm for the current fiscal year ending December 31, 2023 at the 2023-12-31 meeting.
“Proposal 2: Ratification of Appointment of Crowe LLP as the Company's Independent Registered Public Accounting Firm for the current fiscal year ending December 31, 2023. For % Votes Cast For Against Abstained Broker Non-Votes 23,358,598 99.88 % 26,157 6,905 —”
DYADIC INTERNATIONAL INC shareholders approved Election of Class I Directors to hold office until the 2026 Annual Meeting of Shareholders.
“Proposal 1: Election of Class I Directors to hold office until the 2026 Annual Meeting of Shareholders. Nominee For Withheld Broker Non-Votes Seth J. Herbst, M.D. 15,207,883 780,295 7,403,482 Arindam Bose, Ph.D. 15,832,192 155,986 7,403,482”
DYADIC INTERNATIONAL INC shareholders approved Advisory Vote on compensation of the Company's Named Executive Officers. at the 2023-06-09 meeting.
“Proposal 3: Advisory Vote on compensation of the Company's Named Executive Officers. For % Votes Cast For Against Abstained Broker Non-Votes 15,542,578 97.61 % 380,176 58,494 7,410,413”
DYADIC INTERNATIONAL INC shareholders approved Ratification of Appointment of Crowe LLP as the Company's Independent Registered Public Accounting Firm for the current fiscal year ending December 31, 2023. at the 2023-06-09 meeting.
“Proposal 2: Ratification of Appointment of Crowe LLP as the Company's Independent Registered Public Accounting Firm for the current fiscal year ending December 31, 2023. For % Votes Cast For Against Abstained Broker Non-Votes 23,358,535 99.88 % 26,165 6,961 —”
DYADIC INTERNATIONAL INC shareholders approved Election of Class I Directors to hold office until the 2026 Annual Meeting of Shareholders. at the 2023-06-09 meeting.
“Proposal 1: Election of Class I Directors to hold office until the 2026 Annual Meeting of Shareholders. Nominee For Withheld Broker Non-Votes Seth J. Herbst, M.D. 15,200,953 780,295 7,410,413 Arindam Bose, PH.D. 15,825,262 155,986 7,410,413”
DYADIC INTERNATIONAL INC reported financial results for quarter ended March 31, 2023.
“Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments.”
DYADIC INTERNATIONAL INC entered into Expanded Licensing Agreement with Rubic One Health (effective 2023-04-06).
“On April 6, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc., (hereinafter collectively referred to as “Dyadic” or the “Company”) signed an expanded licensing agreement (“the Agreement”) for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to research, develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.”
DYADIC INTERNATIONAL INC engaged Crowe LLP as its auditor.
“On April 10, 2023, the members of the audit committee of the Company approved the engagement of Crowe LLP as the principal accountant to audit the Company’s financial statements.”
DYADIC INTERNATIONAL INC reported financial results for year ended December 31, 2022.
“On March 29, 2023, Dyadic International, Inc. (“Dyadic”, or the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and recent Company progress. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference except for paragraphs two, three, four and five of the press release.”
DYADIC INTERNATIONAL INC: Amended and restated bylaws effective immediately, relating to Rule 14a-19 and recent amendments to the Delaware General Corporation Law (effective 2023-03-28).
“On March 28, 2023, the board of directors (the “Board”) of Dyadic International, Inc. (the “Company”) amended and restated the Company’s Second Amended and Restated Bylaws (as amended and restated, the “Bylaws”), effective immediately. Among other things, the amendments relate to (i) Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (ii) recent amendments to the Delaware General Corporation Law.”
Mayer Hoffman McCann P.C. resigned as auditor of DYADIC INTERNATIONAL INC.
“On February 16, 2023, Mayer Hoffman McCann P.C. (“MHM”), the independent registered public accounting firm to Dyadic International, Inc. (the “registrant”), informed the registrant of its decision to resign from this role effective upon the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”). MHM stated that it is resigning due to its own resource constraints. Neither the registrant’s audit committee nor its board of directors took part in MHM’s decision to resign.”
DYADIC INTERNATIONAL INC entered into Alphazyme Sale Agreement with Alphazyme, LLC valued at approximately US$1.27 million (effective 2023-01-18).
“On January 18, 2023, Dyadic International, Inc. (“Dyadic” or the “Company”) entered into a Securities Purchase Agreement under which the Company agreed to sell its equity interest in Alphazyme, LLC (the "Alphazyme Sale Agreement").”
DYADIC INTERNATIONAL INC reported financial results for the quarter ended September 30, 2022.
“On November 10, 2022, Dyadic International, Inc. ("Dyadic”) issued a press release announcing its results for the quarter ended September 30, 2022.”
Joe Hazelton was appointed as Chief Business Officer at DYADIC INTERNATIONAL INC.
“Mr. Jones’ responsibilities for commercialization and business development will be transitioning to our new Chief Business Officer, Joe Hazelton.”
Matthew Jones departed as Managing Director of Business Development and Licensing at DYADIC INTERNATIONAL INC.
“On April 22, 2022, Dyadic International, Inc. (“Dyadic” or the “Company”) decided not to renew the consulting agreement the Company entered into with Novaro Ltd to engage Matthew Jones as its Managing Director of Business Development and Licensing.”
Joseph Hazelton was appointed as Chief Business Officer at DYADIC INTERNATIONAL INC.
“Effective November 9, 2021, Dyadic International, Inc. (“Dyadic” or the “Company”) appointed Joseph Hazelton, age 46 as its Chief Business Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.